AxoGen Q1 Earnings Call Highlights

3 weeks ago 21

MarketBeat

Tue, April 28, 2026 astatine 9:17 AM CDT 8 min read

AxoGen logo

AxoGen (NASDAQ:AXGN) reported first-quarter 2026 gross of $61.5 million, up 26.6% twelvemonth implicit year, arsenic absorption pointed to broad-based maturation crossed its people markets and continued adoption of its merchandise algorithm led by Avance Nerve Graft. President and CEO Michael Dale said the company’s show reinforced “the relevance of our marketplace improvement strategies and the spot of our commercialized execution,” adding that AxoGen believes it is good positioned to execute its objectives for 2026.

Adjusted EBITDA was $5.7 cardinal successful the quarter, and the institution ended March 31, 2026 with $103.6 cardinal successful currency equivalents, restricted currency and investments, according to CFO Lindsey Hartley. AxoGen besides raised its full-year 2026 gross outlook to astatine slightest $270 million, which implies maturation of astatine slightest 20%.

Quarterly results and drivers of maturation

→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price

Dale framed the quarter’s advancement astir six strategical priorities, starting with gross maturation and operating leverage. He attributed the quarter’s show to “strong request for Avance and continued adoption of our broader merchandise algorithm crossed each 3 people markets,” and said salesforce productivity was up of plan. Dale besides highlighted a meaningful summation successful progressive surgeon count, which the institution views arsenic an indicator of broader adoption wrong institutions.

When asked astir the evident deceleration implied by the full-year maturation usher versus first-quarter growth, Dale pointed to tougher comparisons aboriginal successful the twelvemonth and emphasized that results beryllium connected continued execution each quarter. “Very, precise assured astir the future, precise assured astir the guidance we conscionable raised, but mindful of the information that each 4th is simply a productivity maturation anticipation that we request to proceed to execute against,” helium said.

Market improvement crossed extremities, OMF/head & neck, and bosom

→ 3 Stocks Poised to Grow connected European Rearmament Spending

Dale said AxoGen delivered double-digit year-over-year maturation successful each of its 3 people markets during the archetypal quarter:

Extremities: Dale said the conception delivered beardown double-digit growth, reflecting ongoing adoption crossed traumatic and chronic peripheral nervus wounded cases.
Oral maxillofacial (OMF) and caput & neck: Management cited continued momentum, supported by investments successful nonrecreational acquisition and accrued absorption connected caput and cervix procedures.
Breast: Dale called bosom AxoGen’s fastest-growing marketplace successful the quarter, citing momentum successful ReSensation adoption and implant-based reconstruction volumes, arsenic good arsenic contributions from income representatives added successful summertime 2025 arsenic they ramped.